TNF Pharmaceuticals (TNFA) announced that topline results from a Phase 2a study of its lead drug candidate MYMD-1 was presented at a international congress of global experts in sarcopenia and related disorders held December 6-8 in Washington, D.C. The presentation, ‘Isomyosamine for the Treatment of Sarcopenia in Elderly Population,’ describes the results of a double-blind, placebo-controlled study in patients aged 65 years or older with chronic inflammation associated with sarcopenia/frailty. Subjects in the trial who were given once daily oral doses of MYMD-1 showed significant decreases in several biomarkers attributed to chronic inflammation, including tumor necrosis factor-alpha, Interleukin-6 and soluble TNF-a receptor 1 at several timepoints throughout the 28 days of treatment. No serious adverse events were reported.
Don’t Miss TipRanks’ Half Year Sale
- Take advantage of TipRanks Premium for 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TNFA: